Retrospective Research Of Endostar Combined With Platinum-based Chemotherapy For Advanced Non-small Cell Lung Cancer

Objective:The current study was to investigate the short-term effects and safety of Endostar(Recombinant human endostatin,YH-16) combined with platinum-based chemotherapy for advanced non-small cell lung cancer(NSCLC) and to compare with platinum-based chemotherapy alone.Methods:Following Inclusion criteria,60 advanced NSCLC inpatients were selected from the Department of Oncology of the First Affiliated Hospital of Dalian Medical University from 6/1/2007 to 12/31/2008. Ac- cording to treatment protocols,divided them into two groups:28 patients treated with Endostar plus platinum-based chemotherapy(Study group) and 32 patients treated with platinum-based chemotherapy alone(Control group).Adopting retrospective research,the related data was analyzed and compared.And the response rate(RR),disease control rate(DCR),quality of life(include the variation of ECOG and the relief rate of clinical symptoms) and side reactions were evaluated.Results:The feature of the selected cases:The proportion of more than second-line treatment in study group(25%) was higher than that in control group(0%),and statistical difference existed(P<0.05);ECOG level in study group(1.61±0.29)was higher than that in control group(1.25±1.22),and statistical difference existed(P<0.05).The RR was 10.71% in study group and 12.5% in control group,no statistical difference existed(P>0.05).The DCR was 96.43% in study group and 93.75% in control group,no statistical difference existed(P>0.05).After therapy,ECOG was(1.36±0.32)in study group and(1.06±0.27)in control group,all reduced markedly,and statistical difference existed(P < 0.05),but no statistical difference between two groups(P>0.05).The relief rate of clinical symptoms in study group was higher than that in control group:the relief rate of cough was 80.25% and 71.43%y;the relief rate of short breath was 78.57% and 75%;the relief rate of hemoptysis was 90% and 81.82%;the relief rate of pain was 75% and 71.43%,but no statistical differences existed(P > 0.05).The main side reactions were nausea/vomiting,fatigue,bone marrow depression and so on.Leukopenia and granulopenia were predominant in bone marrow depression.All patients were capable of tolerating the side reactions.And there were no statistical differences between study group and control group(P>0.05).Conclusion:The combination of Endostar with platinum-based che- motherapy had not improved curative effect,besides,not increased side reactions.It has a tendency of improving quality of life and deserves further clinical study.